Axicabtagene Ciloleucel

Follicular lymphoma is among the least common types of non-Hodgkin lymphoma, but the nature of the disease has allowed those who require treatment to benefit from the groundbreaking development of chimeric antigen receptor T cells.

CHICAGO — Axicabtagene ciloleucel exhibited comparable efficacy and safety for large B-cell lymphoma regardless of patients’ race or ethnicity, according to study results presented at ASCO Annual Meeting.

First-line therapy with axicabtagene ciloleucel induced objective responses in 89% of patients with high-risk large B-cell lymphoma, according to phase 2 study results.

Tisagenlecleucel may be less toxic than axicabtagene ciloleucel for patients with relapsed or refractory follicular lymphoma, study results suggested.

Despite a high upfront price, treatment with axicabtagene ciloleucel appeared more cost-effective as second-line therapy than standard treatment for relapsed or refractory large B-cell lymphoma, according to study results.

The addition of utomilumab after infusion with axicabtagene ciloleucel induced a 75% response rate among adults with relapsed or refractory large B-cell lymphoma, data from the ZUMA-11 trial showed.

The FDA approved axicabtagene ciloleucel as second-line treatment for adults with large B-cell lymphoma who are refractory to first-line chemoimmunotherapy or experienced disease relapse within 12 months of initial treatment.

Second-line therapy with axicabtagene ciloleucel conferred a greater than eightfold increase in median EFS compared with standard-of-care treatment for older patients with diffuse large B-cell lymphoma, according to phase 3 study results.

Researchers from Europe and the U.S. developed a hematologic toxicity score that can predict which patients are more likely to develop severe infections after chimeric antigen receptor T-cell therapy.

The FDA updated the prescribing information for axicabtagene ciloleucel to allow the use of prophylactic corticosteroids to manage the severity of certain treatment-related adverse events.